Business Description
Blau Farmaceutica SA
ISIN : BRBLAUACNOR8
Total Employee Number:
1,070Compare
Compare
Traded in other countries / regions
BLAU3.Brazil IPO Date
2021-04-19Description
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.97 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | 1.08 | |||||
Interest Coverage | 2.71 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.28 | |||||
Beneish M-Score | -2.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.6 | |||||
3-Year EBITDA Growth Rate | 0.4 | |||||
3-Year EPS without NRI Growth Rate | -7.1 | |||||
3-Year FCF Growth Rate | -0.1 | |||||
3-Year Book Growth Rate | -1.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.29 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.1 | |||||
9-Day RSI | 24.04 | |||||
14-Day RSI | 30.59 | |||||
3-1 Month Momentum % | -9.3 | |||||
6-1 Month Momentum % | 4.19 | |||||
12-1 Month Momentum % | 4.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.66 | |||||
Quick Ratio | 1.67 | |||||
Cash Ratio | 0.79 | |||||
Days Inventory | 239.61 | |||||
Days Sales Outstanding | 100.76 | |||||
Days Payable | 89.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 7.47 | |||||
Dividend Payout Ratio | 0.5 | |||||
3-Year Dividend Growth Rate | 6.4 | |||||
Forward Dividend Yield % | 3.37 | |||||
5-Year Yield-on-Cost % | 7.41 | |||||
3-Year Average Share Buyback Ratio | -9.1 | |||||
Shareholder Yield % | 7.51 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 40.44 | |||||
Operating Margin % | 18.64 | |||||
Net Margin % | 13.82 | |||||
EBITDA Margin % | 29.52 | |||||
FCF Margin % | 6.86 | |||||
OCF Margin % | 15.68 | |||||
ROE % | 10.71 | |||||
ROA % | 6.87 | |||||
ROIC % | 9.08 | |||||
3-Year ROIIC % | -7.72 | |||||
ROC (Joel Greenblatt) % | 25.02 | |||||
ROCE % | 15.35 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 6.74 | |||||
Forward PE Ratio | 7.36 | |||||
PE Ratio without NRI | 6.7 | |||||
Shiller PE Ratio | 8 | |||||
Price-to-Owner-Earnings | 31.74 | |||||
PEG Ratio | 6.09 | |||||
PS Ratio | 1.18 | |||||
PB Ratio | 0.9 | |||||
Price-to-Tangible-Book | 1.25 | |||||
Price-to-Free-Cash-Flow | 17.57 | |||||
Price-to-Operating-Cash-Flow | 7.52 | |||||
EV-to-EBIT | 4.63 | |||||
EV-to-Forward-EBIT | 5.03 | |||||
EV-to-EBITDA | 3.98 | |||||
EV-to-Forward-EBITDA | 4.25 | |||||
EV-to-Revenue | 1.17 | |||||
EV-to-Forward-Revenue | 1.1 | |||||
EV-to-FCF | 17.38 | |||||
Price-to-GF-Value | 0.8 | |||||
Price-to-Projected-FCF | 0.65 | |||||
Price-to-Graham-Number | 0.61 | |||||
| Price-to-Net-Current-Asset-Value | 3.79 | |||||
Earnings Yield (Greenblatt) % | 21.59 | |||||
FCF Yield % | 5.84 | |||||
Forward Rate of Return (Yacktman) % | 7.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Blau Farmaceutica SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 1,764.355 | ||
| EPS (TTM) (R$) | 1.334 | ||
| Beta | 0.6953 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.36 | ||
| Volatility % | 28.65 | ||
| 14-Day RSI | 30.59 | ||
| 14-Day ATR (R$) | 0.345144 | ||
| 20-Day SMA (R$) | 9.876 | ||
| 12-1 Month Momentum % | 4.23 | ||
| 52-Week Range (R$) | 8.72 - 11.84 | ||
| Shares Outstanding (Mil) | 230.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Blau Farmaceutica SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Blau Farmaceutica SA Stock Events
| Event | Date | Price (R$) | ||
|---|---|---|---|---|
| BRL 0.075763 Cash Dividend | 2026-06-26 | 10.10 (+0.10%) | ||
| BRL 0.075763 Cash Dividend | 2026-03-24 | 10.08 (+2.23%) | ||
| 1.3:1 Stock Split | 2026-01-06 | 11.22 (+2.46%) | ||
| BRL 0.432929 Cash Dividend | 2025-12-19 | 10.04 (+2.19%) | ||
| BRL 0.086586 Cash Dividend | 2025-12-05 | 10.37 (+0.60%) | ||
| BRL 0.073598 Cash Dividend | 2025-09-24 | 10.78 (+0.94%) | ||
| BRL 0.194818 Cash Dividend | 2025-03-24 | 10.15 (-3.23%) | ||
| BRL 0.064939 Cash Dividend | 2024-09-27 | 10.15 (+0.00%) |
Show
Entries
Blau Farmaceutica SA Frequently Asked Questions
What is Blau Farmaceutica SA(BSP:BLAU3)'s stock price today?
The current price of BSP:BLAU3 is R$8.98. The 52 week high of BSP:BLAU3 is R$11.84 and 52 week low is R$8.72.
When is next earnings date of Blau Farmaceutica SA(BSP:BLAU3)?
The next earnings date of Blau Farmaceutica SA(BSP:BLAU3) is .
Does Blau Farmaceutica SA(BSP:BLAU3) pay dividends? If so, how much?
The Dividend Yield % of Blau Farmaceutica SA(BSP:BLAU3) is 7.47% (As of Today), Highest Dividend Payout Ratio of Blau Farmaceutica SA(BSP:BLAU3) was 0.61. The lowest was 0.14. And the median was 0.29. The Forward Dividend Yield % of Blau Farmaceutica SA(BSP:BLAU3) is 3.37%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Brazil Achieves a Historic Milestone: Blau Farmacêutica Fully Develops One of the World's Most Advanced Biosimilars Immunotherapies | 2026-01-23 |
Articles on Blau Farmaceutica SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers